Drug intelligence / Profile preview

TT-01 ADC

Development stage: Preclinical
Lead developer: Topmunnity Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TT-01 ADC is an antibody-drug conjugate (ADC) being developed by Topmunnity Therapeutics for the treatment of various oncology indications. The therapeutic consists of a monoclonal antibody targeting a validated but undisclosed oncology antigen, conjugated via a chemical linker to a cytotoxic payload. TT-01 ADC is specifically engineered to achieve superior internalization rates compared to existing ADCs targeting the same antigen, which is intended to enhance the delivery of the cytotoxic agent into cancer cells and improve therapeutic outcomes. The drug is currently in the IND-enabling stage of development and is designed for use across multiple therapeutic areas in oncology.

Beyond the preview

Go deeper on TT-01 ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TT-01 ADC.

Explore the full profile